Numerous research papers have shown that FXR is crucial in the progression of CRC (Fu et al., 2019; Guo et al., 2022); Yu et al. showed that downregulation of FXR expression promoted CRC progression (Yu et al., 2022); in addition, another study found that FXR could play a tumor suppressor role in CRC by inhibiting Wnt/β-catenin signaling (Yu et al., 2020). This evidence concerns the gene NR1H4 and colorectal carcinoma.